RU2017135552A - Глутамат оксалоацетат трансаминаза 1 (got1), препараты и способы их получения и применения - Google Patents
Глутамат оксалоацетат трансаминаза 1 (got1), препараты и способы их получения и применения Download PDFInfo
- Publication number
- RU2017135552A RU2017135552A RU2017135552A RU2017135552A RU2017135552A RU 2017135552 A RU2017135552 A RU 2017135552A RU 2017135552 A RU2017135552 A RU 2017135552A RU 2017135552 A RU2017135552 A RU 2017135552A RU 2017135552 A RU2017135552 A RU 2017135552A
- Authority
- RU
- Russia
- Prior art keywords
- got1
- sumo
- polypeptide
- fusion protein
- stage
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- 238000002360 preparation method Methods 0.000 title claims 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title claims 3
- 229930195712 glutamate Natural products 0.000 title claims 3
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 title 1
- 102100036608 Aspartate aminotransferase, cytoplasmic Human genes 0.000 claims 18
- 108010026759 Cytoplasmic Aspartate Aminotransferase Proteins 0.000 claims 18
- 102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 claims 10
- 108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 claims 10
- 108020001507 fusion proteins Proteins 0.000 claims 10
- 102000037865 fusion proteins Human genes 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 235000018102 proteins Nutrition 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 238000001556 precipitation Methods 0.000 claims 5
- 238000000746 purification Methods 0.000 claims 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 238000005571 anion exchange chromatography Methods 0.000 claims 2
- 238000005277 cation exchange chromatography Methods 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 101000708016 Caenorhabditis elegans Sentrin-specific protease Proteins 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- 239000001166 ammonium sulphate Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/303—Extraction; Separation; Purification by precipitation by salting out
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01001—Aspartate transaminase (2.6.1.1), i.e. aspartate-aminotransferase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140492P | 2015-03-31 | 2015-03-31 | |
| US62/140,492 | 2015-03-31 | ||
| PCT/IL2016/050346 WO2016157190A1 (en) | 2015-03-31 | 2016-03-31 | Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017135552A true RU2017135552A (ru) | 2019-04-30 |
| RU2017135552A3 RU2017135552A3 (enExample) | 2019-07-24 |
Family
ID=55795016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017135552A RU2017135552A (ru) | 2015-03-31 | 2016-03-31 | Глутамат оксалоацетат трансаминаза 1 (got1), препараты и способы их получения и применения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180071369A1 (enExample) |
| EP (1) | EP3277308A1 (enExample) |
| JP (1) | JP2018511325A (enExample) |
| KR (1) | KR20170132293A (enExample) |
| CN (1) | CN107771217A (enExample) |
| AU (1) | AU2016242298A1 (enExample) |
| BR (1) | BR112017021016A2 (enExample) |
| CA (1) | CA2979309A1 (enExample) |
| HK (1) | HK1243329A1 (enExample) |
| RU (1) | RU2017135552A (enExample) |
| WO (1) | WO2016157190A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018229764A1 (en) | 2017-06-13 | 2018-12-20 | Yeda Research And Development Co. Ltd. | Treatment of advanced or progressive multiple sclerosis |
| RU2712193C1 (ru) * | 2018-07-27 | 2020-01-24 | Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") | Способ лечения поражения нервной системы с помощью рекомбинантной глутаматоксалоацетаттрансаминазы |
| US11740211B2 (en) * | 2020-01-31 | 2023-08-29 | Waters Technologies Corporation | LC/MS adduct mitigation by vapor deposition coated surfaces |
| CN116143898B (zh) * | 2023-01-30 | 2026-03-24 | 翌圣生物科技(上海)股份有限公司 | 骨形态发生蛋白bmp-2重组蛋白、编码基因及其原核表达方法 |
| CN118147225A (zh) * | 2024-03-25 | 2024-06-07 | 华中农业大学 | 黄颡鱼去sumo化修饰体系及其构建方法和应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| CA2472477C (en) * | 2002-01-07 | 2012-03-20 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| EP2561889A3 (en) * | 2002-08-01 | 2013-04-03 | Yeda Research and Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| GB0315248D0 (en) * | 2003-06-30 | 2003-08-06 | Hoffmann La Roche | HCV regulated protein expression |
| EP1765857A2 (en) * | 2004-07-02 | 2007-03-28 | Metanomics GmbH | Process for the production of fine chemicals |
| CA2585798A1 (en) * | 2004-12-17 | 2006-06-17 | Metanomics Gmbh | Process for the control of production of fine chemicals |
| US8119369B2 (en) | 2004-12-30 | 2012-02-21 | Lifesensors, Inc. | Human SUMO-3 for enhancing protein expression |
| US20100048480A1 (en) * | 2006-11-22 | 2010-02-25 | Bettina Bommarius | Production of anti-microbial peptides |
| JP5469786B2 (ja) * | 2006-12-29 | 2014-04-16 | ライフセンサーズ、インク． | タンパク質の発現増強および精製の方法および組成 |
| PT2415779E (pt) * | 2010-08-02 | 2015-05-13 | Ratiopharm Gmbh | Processo de produção e purificação de uma sialiltransferase solúvel activa |
| EP2714727B1 (en) * | 2011-05-24 | 2014-10-22 | Asociación Centro de Investigación Cooperativa en Biociencias-CIC Biogune | High affinity sumo traps |
-
2016
- 2016-03-31 HK HK18102801.5A patent/HK1243329A1/zh unknown
- 2016-03-31 AU AU2016242298A patent/AU2016242298A1/en not_active Abandoned
- 2016-03-31 WO PCT/IL2016/050346 patent/WO2016157190A1/en not_active Ceased
- 2016-03-31 BR BR112017021016-9A patent/BR112017021016A2/pt not_active Application Discontinuation
- 2016-03-31 KR KR1020177031382A patent/KR20170132293A/ko not_active Withdrawn
- 2016-03-31 RU RU2017135552A patent/RU2017135552A/ru not_active Application Discontinuation
- 2016-03-31 EP EP16717478.8A patent/EP3277308A1/en not_active Withdrawn
- 2016-03-31 CA CA2979309A patent/CA2979309A1/en not_active Abandoned
- 2016-03-31 US US15/561,053 patent/US20180071369A1/en not_active Abandoned
- 2016-03-31 JP JP2017550936A patent/JP2018511325A/ja active Pending
- 2016-03-31 CN CN201680031560.0A patent/CN107771217A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018511325A (ja) | 2018-04-26 |
| HK1243329A1 (zh) | 2018-07-13 |
| CN107771217A (zh) | 2018-03-06 |
| WO2016157190A1 (en) | 2016-10-06 |
| US20180071369A1 (en) | 2018-03-15 |
| EP3277308A1 (en) | 2018-02-07 |
| AU2016242298A1 (en) | 2017-10-19 |
| KR20170132293A (ko) | 2017-12-01 |
| RU2017135552A3 (enExample) | 2019-07-24 |
| CA2979309A1 (en) | 2016-10-06 |
| BR112017021016A2 (pt) | 2018-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| HRP20230991T1 (hr) | Inzulin-fc fuzijski proteini ultradugog djelovanja i metode uporabe | |
| RU2011137030A (ru) | Способы очистки малых модулярных иммунофармацевтических белков | |
| JP2015212284A5 (enExample) | ||
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| JP2015524403A5 (enExample) | ||
| JP2017514522A5 (enExample) | ||
| JP2021517805A5 (enExample) | ||
| HRP20171694T1 (hr) | Novi pripravci i postupci | |
| ZA202503137B (en) | Truncated respiratory syncytial virus f protein and use thereof | |
| RU2016108976A (ru) | С5-связующие полипептиды | |
| EA201300056A1 (ru) | Полипептид с активностью ацетилксиланэстеразы и его применения | |
| HRP20250701T1 (hr) | Himerni protein papiloma virusa l1 | |
| JP2014503216A5 (enExample) | ||
| JP2018511325A5 (enExample) | ||
| JP2019505567A5 (enExample) | ||
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| RU2013111675A (ru) | Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc | |
| US20250215050A1 (en) | Compositions and methods for purifying biological fluids | |
| JP2017533182A5 (enExample) | ||
| EA201300059A1 (ru) | Полипептид, обладающий активностью сволленина, и его применение | |
| RU2018141714A (ru) | Слитый белок, содержащий вариант CCL3, и его применение | |
| JP2019503171A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200210 |